Alvin Estilo
Overview
Explore the profile of Alvin Estilo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behl S, Slomkowski M, Chen D, Chang D, Hefting N, Lee D, et al.
J Alzheimers Dis
. 2024 Nov;
102(2):520-529.
PMID: 39534972
Background: A 12-week randomized controlled trial demonstrated that brexpiprazole is efficacious for treating agitation in patients with dementia due to Alzheimer's disease. Objective: To assess the long-term safety and tolerability...
2.
Marquez L, Raheja R, Chan-Liston M, Marcinak J, Estilo A, Pineda Salgado L, et al.
Drug Saf
. 2023 Oct;
47(1):1-22.
PMID: 37874451
The relative treatment benefit of a drug for patients during development, marketing authorization review, or after approval includes an assessment of the risk of drug-induced liver injury (DILI). In this...
3.
Estilo A, Tracy L, Matthews C, Riggen M, Stemhagen A, Wilt T, et al.
Clin Kidney J
. 2023 Feb;
15(8):1553-1561.
PMID: 36824061
Background: On approval of JYNARQUE (tolvaptan) for use in patients with autosomal dominant polycystic kidney disease (ADPKD) at risk for rapid progression, the US Food and Drug Administration required a...
4.
Alpers D, Lewis J, Hunt C, Freston J, Torres V, Li H, et al.
Am J Kidney Dis
. 2022 Oct;
81(3):281-293.e1.
PMID: 36191725
Rationale & Objective: Tolvaptan is associated with risk of drug-induced liver injury when used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was described based on the...
5.
Estilo A, McCormick L, Rahman M
Adv Ther
. 2021 Oct;
38(12):5721-5736.
PMID: 34693505
Introduction: Hyponatremia is a common condition of varying etiology among hospitalized patients and is associated with adverse outcomes. Treatment to normalize serum sodium is advisable. Tolvaptan received European Union marketing...
6.
Pineda Salgado L, Gupta R, Jan M, Turkoglu O, Estilo A, George V, et al.
Adv Ther
. 2021 Jul;
38(9):4709-4721.
PMID: 34319549
Introduction: Drug-induced liver injury (DILI) is the most frequent cause of acute liver failure in North America and Europe, but it is often missed because of unstandardized diagnostic methods and...
7.
Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, et al.
Drug Saf
. 2021 Mar;
44(6):619-634.
PMID: 33725335
Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject...
8.
Torres V, Chapman A, Devuyst O, Gansevoort R, Perrone R, Lee J, et al.
Clin J Am Soc Nephrol
. 2020 Dec;
16(1):48-58.
PMID: 33376102
Background And Objectives: Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. In the 3-year Tolvaptan Efficacy and Safety in...
9.
Shoaf S, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D
Clin J Am Soc Nephrol
. 2020 Apr;
15(5):643-650.
PMID: 32241780
Background And Objectives: Tolvaptan is approved to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Because studies indicated that the...